Source-grounded facts extracted from Connect Biopharma Holdings Ltd's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Connect Biopharma Holdings Ltd reported the three months ended March 31, 2026 results: revenue $0.2 million, net income $19.4 million, EPS ($0.34) per share.
“its cash and investments will be sufficient to fund operations into the second half of 2027. • License and collaboration revenues for the three months ended March 31, 2026 were $0.2 million related to the upfront license fee under the license agreement with Simcere. There were no license and collaboration revenues for the three months ended March 31, 2025. As a part”
Earnings Releases
Connect Biopharma Holdings Ltd reported financial results for the three and twelve months ended December 31, 2025.
“On March 31, 2026, Connect Biopharma Holdings Limited (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025.”
Equity Issuances
Connect Biopharma Holdings Ltd issued 6,130,000 shares of common stock to institutional accredited investors for $3.25 per Share.
“On March 29, 2026, Connect Biopharma Holdings Limited (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with the purchasers named therein (the "Purchasers"), for the private placement (the "Private Placement") of 6,130,000 shares (the "Shares") of the Company's ordinary shares, par value $0.000174 per share (the "Ordinary Shares"), at a price of $3.25 per Share with respect to any Purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company.”
Material Agreements
Connect Biopharma Holdings Ltd entered into Purchase Agreement with the purchasers named therein valued at approximately $20.2 million (effective 2026-03-29).
“On March 29, 2026, Connect Biopharma Holdings Limited (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 6,130,000 shares (the “Shares”) of the Company’s ordinary shares, par value $0.000174 per share (the “Ordinary Shares”), at a price of $3.25 per Share”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.